THE POSSIBILITIES OF OPTIMIZING THE COSTS OF DRUG PROVISION TO PATIENTS DUE TO THE CENTRALIZED DILUTION OF ANTITUMOR DRUGS

Abstract

The high level of costs for chemotherapy of malignant neoplasms requires the search for new solutions to reduce the cost of treatment. Centralized dilution of drugs is one of the most optimal solutions to this problem. But making such a decision requires a rather laborious calculation of the expected economic effects. The purpose of the study was to substantiate the economic benefits of centralized dilution of chemotherapeutic drugs in the regional oncological hospital. As materials, we took into account the number of spent 62 injectable forms of antitumor drugs in the departments of the Sverdlovsk Regional Oncological Dispensary, information on the implementation of 2098 chemotherapy regimens, acts on the disposal of unused drug residues, state contracts for the supply of drugs in 2022-2023. Methods of economic and mathematical analysis, modeling of economic situations with calculation of economic indicators were used to determine direct absolute and relative losses during the disposal of drug residues, as well as calculation of prevented economic damage. As a result, indicators were developed to determine the economic efficiency of the centralized drug dilution: the specific drug weight in the prescribing lists, absolute and relative financial losses, loss reduction coefficient. The relationship between the frequency of prescriptions and the potential for possible savings due to rational utilization of drug residues has been established. The average level of relative drug losses after the introduction of centralized drug dilution was 0.09% in 2023 against 5.54% of losses in 2022. The economic feasibility of using centralized drug dilution in large medical organizations is substantiated. The introduction of a centralized drug dilution in the Sverdlovsk Regional Oncology Dispensary prevented more than 20 million rubles of economic damage per month.